Peripheral Nerve Stimulator wins FDA clearance for pain management — 5 insights

The FDA cleared SPR Therapeutics' Sprint single-lead endura and dual-lead extensa peripheral nerve stimulation systems. 

Here are five insights:

1. The Sprint System is the only FDA-cleared percutaneous PNS system indicated for up to 60 days of therapy in the back and/or extremities for chronic and acute pain.

2. The Sprint System is also the industry’s only PNS platform with dual-led capability. The dual-lead capability allows physicians to implant two leads connected to a single wearable pulse generator.

3. Physicians can place the Sprint PNS system leads without surgery, incisions, tissue destruction or anesthesia during outpatient procedures.

4. Preliminary results from a multicenter study evaluating Sprint showed the therapy was associated with significant reduction in chronic post-amputation pain among two-thirds of subjects, after eight weeks of treatment. Four of five patients reported enduring and significant pain relief.

5. SPR Therapeutics aims to advance the early use of neurostimulation as a non-opioid alternative.

More articles on anesthesia:
BlueCross, Anesthesia Medical Group stalemate could cost patients thousands — 6 details
Johns Hopkins panel develops opioid prescribing guidelines for 20 common operations
FDA recalls SpaceLabs anesthesia system 3rd time, for 'failed state': 5 details

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months